Source comparison
PT-141 vs Viagra Mechanism: Research Application Comparison
Primary Target MC3R/MC4R melanocortin receptors in hypothalamus PDE5 enzyme in corpus cavernosum smooth muscle PT-141 tests central arousal; Viagra tests peripheral vascular function. Select based on research pathway Mechanism of Action Activates cAMP → PKA si
This comparison does not assign a generated winner or score.
- Primary Target
- MC3R/MC4R melanocortin receptors in hypothalamus
- PDE5 enzyme in corpus cavernosum smooth muscle
- PT-141 tests central arousal; Viagra tests peripheral vascular function. Select based on research pathway
- Mechanism of Action
- Activates cAMP → PKA signalling → dopamine/oxytocin release in CNS
- Inhibits PDE5 → sustains cGMP → smooth muscle relaxation in penile tissue
- PT-141 initiates arousal; Viagra amplifies existing arousal. Different experimental endpoints
- Stimulation Requirement
- No sexual stimulation required for effect
- Requires sexual arousal to produce NO release
- PT-141 useful for studying spontaneous arousal; Viagra for studying stimulus-response coupling
- Administration Route
- Subcutaneous injection
- Oral tablet
- PT-141 requires injection technique; Viagra allows simpler dosing in behavioural studies
- Onset of Action
- 30–60 minutes (peak at 1 hour)
- 30–120 minutes (delayed by food)
- PT-141 faster in fasted state; Viagra onset variable with meal timing
- Duration of Effect
- 6–12 hours (behavioural effects)
- 4–6 hours (vascular effects)
- PT-141 longer subjective duration despite shorter half-life. Active metabolites likely
- Nitrate Interaction
- None. Doesn't affect NO-cGMP pathway
- Absolute contraindication. Severe hypotension risk
- PT-141 safer in models where nitrate use is a confounding variable
- Primary Side Effects
- Nausea (18–25%), BP elevation (10–15 mmHg), flushing
- Headache (16%), visual changes (3–10%), flushing
- PT-141 GI/autonomic; Viagra vascular/sensory. Both dose-dependent